---
title: "Niche Plays Drive Hong Kong's Fringe Market as mRNA, Robotics Gain Traction"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302392104.md"
description: "CRRC's Mexican rail win, Evergreen MedSci's mRNA talent coup, and Joyson's Tesla robotics link highlight structural shifts in Hong Kong's overlooked sectors, while policy headwinds batter CDMO leaders like Asymchem."
datetime: "2026-10-20T09:17:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302392104.md)
  - [en](https://longbridge.com/en/news/302392104.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302392104.md)
generator: "portal-rs"
---

# Niche Plays Drive Hong Kong's Fringe Market as mRNA, Robotics Gain Traction

Hong Kong's overlooked equities are carving divergent paths amid broader market stagnation. Evergreen MedSci (1952.HK) surged 8% intraday after recruiting key architects of Moderna's mRNA-4157 cancer vaccine, positioning its self-owned platform as a rare China-based alternative in the global mRNA race. The move comes as CRRC (1766.HK) gains momentum from its Mexican rail contract, with new energy segment revenues jumping 62.63% sequentially in Q2 2026.

Meanwhile, Joyson Electronics (0699.HK) exemplifies the robotics supply chain spillover effect—its Hong Kong shares spiked 10% when Tesla initiated Optimus production audits in Ningbo, though profit-taking erased most gains by week's end. Asymchem (6821.HK) tells a contrasting story: despite Goldman Sachs' upbeat CDMO sector forecast, the stock plunged 11.85% following regulatory concerns over export controls on biotech know-how.

Traditional sectors show stark contrasts. Energy & Power Global (1142.HK) saw volatile swings after its 10-for-1 share consolidation, while Wanhui Technology (0894.HK) tumbled 19% amid passive component demand slump. Zhonghui Group (0382.HK) reported declining domestic education revenue but 24.25% overseas growth, and Tongtian Winery (0389.HK) posted 47.58% annual revenue growth despite wine industry headwinds.

### Related Stocks

- [00389.HK](https://longbridge.com/en/quote/00389.HK.md)
- [00894.HK](https://longbridge.com/en/quote/00894.HK.md)
- [00382.HK](https://longbridge.com/en/quote/00382.HK.md)
- [01766.HK](https://longbridge.com/en/quote/01766.HK.md)
- [01952.HK](https://longbridge.com/en/quote/01952.HK.md)
- [00699.HK](https://longbridge.com/en/quote/00699.HK.md)
- [01142.HK](https://longbridge.com/en/quote/01142.HK.md)
- [06821.HK](https://longbridge.com/en/quote/06821.HK.md)

## Related News & Research

- [Asymchem Laboratories Tianjin Discloses Share Repurchase in HKEX Next Day Return](https://longbridge.com/en/news/306246115.md)
- [Everest Medicines Doses First Patient in VIS-101 Phase 2b Trial](https://longbridge.com/en/news/306219907.md)
- [Everest Medicines Holds Extraordinary General Meeting](https://longbridge.com/en/news/305664815.md)
- [Everest Medicines Adds Two Drugs to China's Reimbursement List](https://longbridge.com/en/news/305665261.md)
- [Citi: 2026 NRDL Negotiation Results Released; Drugmakers Say Price Cuts Mild and Manageable](https://longbridge.com/en/news/306083646.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**